<DOC>
	<DOC>NCT02483325</DOC>
	<brief_summary>Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible HLA.</brief_summary>
	<brief_title>Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Inclusion Criteria : Informed consent signed, Patient affiliated to a social security system or benefiting from such a system, Related HLA identical donor or unrelated HLA identical donor : all patients aged &gt; 55 years with hematological malignancy and deemed eligible for an allogeneic transplant from a genoidentical donor and phenoidentical 10/10 the basic pathology should be considered "chemosensitive" complete or partial remission (CR, PR) or stable disease Exclusion Criteria : Pregnant or lactating woman or without contraception (for child bearing potential women) Patient deprived of liberty or under supervision of a guardian Impossibility to undergo medical examinations of the study for geographical, social or psychological reasons Usual contraindications for allogenic transplant Aged &lt; 55 years History of allogenic transplant Concomitant neoplastic disease Evolutive psychiatric disease HIV seropositivity or C hepatitis under treatment Women of childbearing age or man, in the absence of effective contraception during treatment and up to 12 months after treatment discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>